Clinical Trial Update: Observational Study of Afatinib 30 mg Daily

View source ↗

Summary

Observational study evaluating afatinib 30 mg daily for non-small cell lung cancer with EGFR mutation; currently recruiting at National University Hospital, Sin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gilotrif (Afatinib)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor Mutation | Status: RECRUITING